The NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved for GSK’s Nucala (mepolizumab) for the treatment of adults ...

Rhythm Technologies announced that it received approval in Japan for its Zio long-term continuous monitoring (LTCM) system.

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...

King of Prussia, Pennsylvania Monday, September 16, 2024, 17:00 Hrs [IST] ...

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.

Osaka Metropolitan University researchers analyzed the incidence in Japan of COVID-19-associated pulmonary aspergillosis ...

Investigating Japanese longevity reveals the impact of lifestyle medicine and government strategies on health, offering ...

(RTTNews) - iRhythm Technologies, Inc. (IRTC), a digital health care company, Wednesday said it has received approval from the Japanese ...

1 CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a ...

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved for GSK’s Nucala (mepolizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) whose ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...